Co-Authors
This is a "connection" page, showing publications co-authored by Özlem Türeci and Ugur Sahin.
Connection Strength
7.830
-
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021 07; 595(7868):572-577.
Score: 0.948
-
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2021 Feb; 590(7844):E17.
Score: 0.927
-
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020 10; 586(7830):594-599.
Score: 0.906
-
Challenges towards the realization of individualized cancer vaccines. Nat Biomed Eng. 2018 08; 2(8):566-569.
Score: 0.779
-
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer. 2018 09; 100:17-26.
Score: 0.773
-
Personalized vaccines for cancer immunotherapy. Science. 2018 Mar 23; 359(6382):1355-1360.
Score: 0.760
-
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017 07 13; 547(7662):222-226.
Score: 0.723
-
BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021 04; 592(7853):283-289.
Score: 0.232
-
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 2021 03 12; 371(6534):1152-1153.
Score: 0.232
-
HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. Oncoimmunology. 2019; 8(9):e1629259.
Score: 0.208
-
Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. Oncoimmunology. 2019; 8(7):1601480.
Score: 0.205
-
Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide. J Nanobiotechnology. 2018 Apr 13; 16(1):39.
Score: 0.191
-
Erratum: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat Med. 2017 10 06; 23(10):1241.
Score: 0.184
-
Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins. Hum Gene Ther. 2017 12; 28(12):1138-1146.
Score: 0.183
-
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat Med. 2017 Jul; 23(7):815-817.
Score: 0.180
-
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021 07 15; 385(3):239-250.
Score: 0.059
-
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med. 2021 06; 27(6):1062-1070.
Score: 0.059
-
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2021 Feb; 590(7844):E26.
Score: 0.058
-
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 12 31; 383(27):2603-2615.
Score: 0.057
-
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 12 17; 383(25):2439-2450.
Score: 0.057
-
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 10; 586(7830):589-593.
Score: 0.056
-
Personalized Neo-Epitope Vaccines for Cancer Treatment. Recent Results Cancer Res. 2020; 214:153-167.
Score: 0.054